Payment overview · 2025
General Payments
$121,000.93
208 reported records · 15 companies
Healthcare provider profile · identity verified
Robert H Stewart, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · LOUISVILLE, KY · NPI 1750423034
Verified facts
What the public records show
CMS Open Payments records show Robert H Stewart, M.D. received $121,000.93 in general payments during 2025 across 208 reported records.
ABBVIE INC. accounted for 46.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Caplyta, Ingrezza, Trintellix.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Auvelity by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Caplyta by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ingrezza by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56,691.65 | 46.9% | 66 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30,581.24 | 25.3% | 50 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20,143.82 | 16.6% | 21 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $12,691.42 | 10.5% | 19 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $238.57 | 0.2% | 7 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $202.90 | 0.2% | 17 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $163.30 | 0.1% | 14 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $75.43 | 0.1% | 3 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $44.48 | 0.0% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $41.60 | 0.0% | 2 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $33.10 | 0.0% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $31.47 | 0.0% | 2 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $29.34 | 0.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.49 | 0.0% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $15.12 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $87,540.00 | 35 |
| Honoraria | $18,975.00 | 7 |
| Consulting Fee | $5,500.00 | 2 |
| Travel and Lodging | $4,984.18 | 29 |
| Food and Beverage | $3,922.25 | 134 |
| Education | $79.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $53,520.14 | 64 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30,581.24 | 50 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20,143.82 | 21 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $12,691.42 | 19 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $202.90 | 17 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $163.30 | 14 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $150.17 | 13 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $134.80 | 5 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $127.17 | 5 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $75.43 | 3 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $71.08 | 4 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $44.48 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $41.60 | 2 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $33.10 | 1 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $33.10 | 1 | 2025 |
Source payment records
|
|||||
| OMNIGRAFT Normalized: omnigraft |
Device | Integra LifeSciences Corporation | $33.10 | 1 | 2025 |
Source payment records
|
|||||
| SURGIMEND Normalized: surgimend |
Device | Integra LifeSciences Corporation | $33.10 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $31.47 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $29.34 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $29.34 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $15.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clonazepam | Clonazepam | 208 | 30 |
| Alprazolam | Alprazolam | 162 | 27 |
| Lorazepam | Lorazepam | 158 | 38 |
| Trazodone Hcl | Trazodone Hcl | 133 | 25 |
| Bupropion Hcl Sr | Bupropion Hcl | 128 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 124 | 34 |
| Lamotrigine | Lamotrigine | 117 | 21 |
| Gabapentin | Gabapentin | 113 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 85 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 13 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 64 | suppressed |
| Bupropion Xl | Bupropion Hcl | 63 | 16 |
| Olanzapine | Olanzapine | 52 | 16 |
| Methylphenidate Hcl | Methylphenidate Hcl | 48 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 46 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 44 | 12 |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 41 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 36 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Modafinil | Modafinil | 28 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Omeprazole | Omeprazole | 25 | suppressed |
| Quviviq | Daridorexant Hcl | 24 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Armodafinil | Armodafinil | 20 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 19 | suppressed |
| Caplyta | Lumateperone Tosylate | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 17 | suppressed |
| Alprazolam Er | Alprazolam | 16 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 16 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Metformin Hcl | Metformin Hcl | 12 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Triazolam | Triazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $121,000.93 · 208 records | ABBVIE INC. | APLENZIN, ARISTADA, AUSTEDO XR, Auvelity, CAPLYTA, Dyanavel XR, FANAPT, HETLIOZ, INGREZZA, Integra, Integra Dermal Regeneration Template, Kerecis GraftGuide, Kerecis SurgiClose, LOREEV XR, LYBALVI, OMNIGRAFT, REXULTI, SURGIMEND, TRINTELLIX, UZEDY, VRAYLAR, WELLBUTRIN, Xelstrym | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Axsome Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error